Acinetobacter Infections – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Acinetobacter Infections – Drugs In Development, 2023’, provides an overview of the Acinetobacter Infections pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Acinetobacter Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acinetobacter Infections and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Acinetobacter Infections
- The report reviews pipeline therapeutics for Acinetobacter Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Acinetobacter Infections therapeutics and enlists all their major and minor projects
- The report assesses Acinetobacter Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Acinetobacter Infections
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Acinetobacter Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Acinetobacter Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
AbGenics Life Sciences Pvt LtdAGILeBiotics BV
AJK Biopharmaceutical LLC
Alterity Therapeutics Ltd
Antabio SAS
Arch Biopartners Inc
Aridis Pharmaceuticals Inc
Armata Pharmaceuticals Inc
AstraZeneca Plc
Atterx Biotherapeutics Inc
Aurora Oncology Inc
Bactobio Ltd
Bioharmony Therapeutics Inc
Biological Anti-Infective Medicines LLC
Biomendics LLC
Bioversys AG
Brii Biosciences Ltd
Bugworks Research Inc
Celdara Medical LLC
Centauri Therapeutics Ltd
Clarametyx Biosciences Inc
ContraFect Corp
Danuvius BioSciences
Debiopharm International SA
Entasis Therapeutics Holdings Inc
F. Hoffmann-La Roche Ltd
Fedora Pharmaceuticals Inc
Hsiri Therapeutics LLC
Idorsia Pharmaceutical Ltd
Inhibrx Inc
Institute for Development Research
Jiangsu Yahong Meditech Co Ltd
KBP Biosciences Co Ltd
King's College London
Linnaeus Bioscience Inc
Meiji Seika Pharma Co Ltd
Melinta Therapeutics LLC
MetalloBio Ltd
Mutabilis SA
Nektr Technologies Ltd
Neoculi Pty Ltd
NYU Langone Health System
Omnix Medical Ltd
Oxford Drug Design Ltd
Pedanius Therapeutics Ltd
Peptilogics Inc
Pfizer Inc
Pylum Biosciences Inc
Qpex Biopharma Inc
Recce Pharmaceuticals Ltd
Redx Pharma Plc
RMH Sciences LLC
Shanghai High-Tech Bioengineering Co Ltd
Shanghai Space Peptides Pharmaceutical Co Ltd
Shionogi & Co Ltd
Spero Therapeutics Inc
Spexis AG
Summit Therapeutics Inc
Telum Therapeutics SL
The Broad Institute Inc
The Lundquist Institute
U.S. Department of Veterans Affairs
University College Dublin
University of Bern
University of Hong Kong
University of Michigan
University Pompeu Fabra
Vanderbilt University
Vaxdyn SL
VenatoRx Pharmaceuticals Inc
Venus Medicine Research Centre
Walter Reed Army Institute of Research
Wayne State University
Xellia Pharmaceuticals ApS
Zai Lab Ltd